(ANTX) (ANTX) News Today → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Free ANTX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesInsider TradesSocial MediaStock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesInsider TradesSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineMaintaining Caution: AN2 Therapeutics Hold Rating Amidst Epetraborole Trial Uncertaintiesmarkets.businessinsider.com - April 9 at 3:40 AMBuy Rating Affirmed for AN2 Therapeutics Amidst Upcoming Catalysts and Strong Valuation Prospectsmarkets.businessinsider.com - April 2 at 7:50 AMANTX Stock Earnings: AN2 Therapeutics Beats EPS for Q4 2023markets.businessinsider.com - March 29 at 1:13 AMAN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific Highlightsbusinesswire.com - March 28 at 4:10 PMSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of AN2 Therapeutics, Inc. - ANTXprnewswire.com - March 11 at 8:17 PMSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of AN2 Therapeutics, Inc. - ANTXprnewswire.com - March 3 at 10:30 AMSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of AN2 Therapeutics, Inc. - ANTXprnewswire.com - February 24 at 10:00 AMSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of AN2 Therapeutics, Inc. - ANTXmarkets.businessinsider.com - February 17 at 6:34 PMSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of AN2 Therapeutics, Inc. - ANTXprnewswire.com - February 15 at 6:20 PMAN2 Therapeutics just downgraded at Evercore ISI, here's whyrealmoney.thestreet.com - February 14 at 1:16 PMAN2 Therapeutics shares fall after pausing lung disease study enrollmentreuters.com - February 13 at 5:14 PMAN2 Therapeutics just downgraded at Leerink, here's whyrealmoney.thestreet.com - February 13 at 2:13 AMAN2 Therapeutics, Inc. (ANTX) was downgraded to a Hold Rating at JMP Securitiesmarkets.businessinsider.com - February 12 at 9:12 PMAN2 Therapeutics Shares Drop 73% After Pausing Enrollment for Epetraborole Trialmarketwatch.com - February 12 at 4:12 PMJMP Securities gets more bearish on AN2 Therapeutics, downgrades sharesrealmoney.thestreet.com - February 12 at 4:12 PMAN2 Therapeutics just downgraded at Oppenheimer, here's whyrealmoney.thestreet.com - February 12 at 4:12 PMAN2 Therapeutics to pause lung disease study enrollmentreuters.com - February 12 at 7:50 AMAN2 Therapeutics Stock Plummets On Decision To Pause Enrollment In Epetraborole Phase 2/3 Trialmarkets.businessinsider.com - February 12 at 7:50 AMAN2 to Voluntarily Pause Enrollment in Phase 3 Part of Phase 2/3 Pivotal Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium Avium Complex (MAC) Lung Diseasefinance.yahoo.com - February 12 at 7:50 AMAN2 Therapeutics Inc Chief Strategy Officer Kevin Krause Sells 7,417 Sharesfinance.yahoo.com - January 12 at 9:48 AMRecent Price Trend in AN2 Therapeutics, Inc. (ANTX) is Your Friend, Here's Whyfinance.yahoo.com - January 10 at 12:45 PMThese Biotech Stocks Caught Our Attention - Did You Notice?markets.businessinsider.com - December 16 at 9:02 AMOne AN2 Therapeutics Insider Raised Their Stake In The Previous Yearfinance.yahoo.com - November 12 at 8:08 AMAN2 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business and Scientific Highlightsfinance.yahoo.com - November 9 at 7:39 PMAN2 Therapeutics, Inc. (ANTX) Is a Great Choice for 'Trend' Investors, Here's Whyfinance.yahoo.com - November 6 at 1:07 PMAN2 Therapeutics Signs License Agreement with the University of Georgia Research Foundation to Develop Novel Boron-Based Therapy for Chagas Diseasefinance.yahoo.com - October 18 at 7:56 AMPromising Outlook for AN2 Therapeutics, Inc.: Buy Rating Conferred Amid Anticipated Ph.2 Results and Encouraging Epetraborole Developmentsmarkets.businessinsider.com - October 17 at 5:33 AMAN2 Therapeutics, Inc. (NASDAQ:ANTX) stock most popular amongst individual investors who own 29%, while private equity firms hold 27%finance.yahoo.com - October 16 at 7:46 AMAN2 Therapeutics to Present New Data for Epetraborole at IDWeek 2023finance.yahoo.com - October 11 at 5:57 AMWhy Wall Street investors are freaking outmsn.com - October 4 at 8:22 PMIs Adagene (ADAG) Outperforming Other Medical Stocks This Year?finance.yahoo.com - September 27 at 1:15 PMAN2 Therapeutics Signs Grant Agreement to Discover Novel, Boron Based Therapies for Tuberculosis and Malariafinance.yahoo.com - September 26 at 9:53 AMAN2 Therapeutics commences Phase 3 Part of Phase 2/3 Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium complex (MAC) Lung Diseasefinance.yahoo.com - September 13 at 10:24 AMHas AN2 Therapeutics (ANTX) Outpaced Other Medical Stocks This Year?finance.yahoo.com - September 11 at 4:07 PMHedge Fund and Insider Trading News: George Soros, Ray Dalio, Crispin Odey, Three Arrows Capital (3AC), Cassava Sciences Inc (SAVA), AN2 Therapeutics, Inc. (ANTX), and Moreinsidermonkey.com - August 25 at 3:03 PMAN2 Therapeutics Announces Pricing of $70.0 Million Underwritten Offering of Common Stockfinance.yahoo.com - August 16 at 2:17 AMAN2 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Highlightsfinance.yahoo.com - August 10 at 6:12 PMCompanies Like AN2 Therapeutics (NASDAQ:ANTX) Are In A Position To Invest In Growthfinance.yahoo.com - June 14 at 9:57 AMAN2 Therapeutics to Present at Jefferies Healthcare Conferencefinance.yahoo.com - May 25 at 7:49 PMAN2 Therapeutics Reports First Quarter 2023 Financial Results and Recent Highlightsfinance.yahoo.com - May 11 at 8:36 PMAN2 Therapeutics, Inc.'s (NASDAQ:ANTX) market cap dropped US$43m last week; individual investors who hold 33% were hit as were institutionsfinance.yahoo.com - May 9 at 10:44 AMAN2 Therapeutics to Present at JMP Securities Life Sciences Conferencefinance.yahoo.com - May 1 at 7:30 AMLina Hidalgo photographed by the legendary Annie Leibovitz for Vogue magazinemsn.com - April 26 at 2:52 PMOppenheimer Reaffirms Their Buy Rating on AN2 Therapeutics, Inc. (ANTX)markets.businessinsider.com - March 30 at 12:08 PMAN2 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlightsfinance.yahoo.com - March 29 at 9:05 PMWill AN2 Therapeutics' Potential MAC Lung Disease Drug Pose Strong Competition To Approved Arikayce?markets.businessinsider.com - March 24 at 1:41 PMAN2 Therapeutics to Participate in Upcoming Investor Conferencesfinance.yahoo.com - February 28 at 10:24 PMGlobal Auto Dialers Market Size Research Report by Growth, Trends, Revenue, Share, Demands and Competitive Analysis 2023-2028marketwatch.com - February 4 at 4:55 AMAN2 Therapeutics to Present at SVB Securities Global Biopharma Conferencefinance.yahoo.com - January 31 at 6:52 PMAuto Dialers Market Share, Size 2023 Global Industry Forecasts Growth, Analysis, Company Profiles, Competitive Landscape and Key Regions Analysismarketwatch.com - January 12 at 8:41 AM Get (ANTX) News Delivered to You Automatically Sign up to receive the latest news and ratings for ANTX and its competitors with MarketBeat's FREE daily newsletter. Email Address World’s biggest multibillionaire investor is buying THIS by the ton [picture] (Ad)Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea. Click here to find out what to do. ANTX Media Mentions By Week ANTX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ANTX News Sentiment▼0.000.42▲Average Medical News Sentiment ANTX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ANTX Articles This Week▼00▲ANTX Articles Average Week Get (ANTX) News Delivered to You Automatically Sign up to receive the latest news and ratings for ANTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: MNOV News Today TPST News Today CUE News Today CRVS News Today ASRT News Today DERM News Today ANEB News Today LPTX News Today CARM News Today SLS News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:ANTX) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarThese AI trades triggered this morning (545% return)Prosper Trading AcademyRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldYour Money is Not SafeAmerican Alternativetop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyThe World's First "$20 Trillion Drug?"Behind the MarketsThe AI stock to buy right nowStockEarnings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding (ANTX) Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
